Clinical trial
Maximizing the Benefit of RAS Blockade in Diabetic Nephropathy
NCT00240019 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Maximizing the Benefit of RAS Blockade in Diabetic Nephropathy
- Lead sponsor
- Stanford University
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- December 31, 2003
- Completion date
- April 30, 2006
- Enrollment
- 30
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
diabetic nephropathy